Key result
Angiopeptin significantly decreased the incidence of death, myocardial infarction, CABG, or repeat PTCA at 12 months compared to placebo (28.4% vs 36.4%; P=0.046).
Why the study?
Does angiopeptin reduce the composite of death, myocardial infarction, coronary artery bypass surgery, or repeat PTCA in patients undergoing percutaneous transluminal coronary angioplasty?
Population
553 patients with 742 lesions undergoing percutaneous transluminal coronary angioplasty (PTCA)
Comparison
Angiopeptin continuous subcutaneous infusion 6… vs Matching placebo continuous subcutaneous…
Design
RCT, randomized, double-blind, placebo controlled
Follow-up
12 months
Authors
Loading...
Reduces clinical events post-PTCA without angiographic benefit; challenges restenosis as a reliable surrogate endpoint.
RCT (n=553)
Double-blind
randomized
Does angiopeptin reduce the composite of death, myocardial infarction, coronary artery bypass surgery, or repeat PTCA in patients undergoing percutaneous transluminal coronary angioplasty?
Absolute Event Rate: 28.4% vs 36.4%
p-value: p=.046
Angiopeptin treatment around the time of PTCA reduces long-term clinical events, primarily driven by a reduction in revascularization procedures, without affecting angiographic restenosis.
Emanuelsson et al. (1995) conducted an RCT in Coronary angioplasty (n=553). Angiopeptin vs. Placebo was evaluated on death, myocardial infarction, coronary artery bypass surgery, or repeat PTCA (p=.046). Angiopeptin significantly decreased the incidence of death, myocardial infarction, CABG, or repeat PTCA at 12 months compared to placebo (28.4% vs 36.4%; P=0.046).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: